RESUMO
BACKGROUND: Visceral leishmaniasis has now emerged as an important opportunistic disease in patients coinfected with human immunodeficiency virus type-1 (HIV-1). Although the effectiveness of HIV-1 protease inhibitors, such as nelfinavir, in antiretroviral therapies is well documented, little is known of the impact of these drugs on Leishmania in coinfected individuals. METHODOLOGY AND PRINCIPAL FINDINGS: Here, we show that nelfinavir generates oxidative stress in the parasite, leading to altered physiological parameters such as an increase in the sub-G1 DNA content, nuclear DNA fragmentation and loss of mitochondrial potential, which are all characteristics of apoptosis. Pretreatment of axenic amastigotes with the caspase inhibitor z-VAD-fmk did not inhibit the increase in sub-G1 DNA content in nelfinavir-treated parasites, suggesting therefore that this antiviral agent does not kill Leishmania amastigotes in a caspase-dependent manner. Furthermore, we observed that the mitochondrial resident protein endonuclease G is involved. We also demonstrate that parasites overexpressing GSH1 (the rate limiting enzyme of glutathione biosynthesis) were more resistant to nelfinavir when compared to untransfected controls. CONCLUSIONS AND SIGNIFICANCE: These data suggest that nelfinavir induces oxidative stress in Leishmania amastigotes, culminating in caspase-independent apoptosis, in which DNA is degraded by endonuclease G. This study provides a rationale for future, long-term design of new therapeutic strategies to test nelfinavir as a potential antileishmanial agent as well as for possible future use in Leishmania/HIV-1 coinfections.
Assuntos
Antiprotozoários/farmacologia , Apoptose , Leishmania/efeitos dos fármacos , Nelfinavir/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Animais , Caspases/metabolismo , Fragmentação do DNA , Endodesoxirribonucleases/metabolismo , Potencial da Membrana MitocondrialRESUMO
Visceral leishmaniasis is now recognized as an opportunistic disease in individuals infected with human immunodeficiency virus type 1 (HIV-1). Although the usefulness of HIV-1 protease inhibitors (PIs) in antiretroviral regimens is well documented, little is known about their potential impact in the setting of Leishmania/HIV-1 coinfections. We now report that, although selected PIs do not inhibit the growth of Leishmania infantum promastigotes alone in culture, these drugs significantly inhibit the intracellular survival of parasites in phorbol myristate acetate-differentiated THP-1 macrophages and human primary monocyte-derived macrophages (MDMs). Furthermore, a field isolate of Leishmania donovani resistant to sodium stibogluconate (SbV), one of the drugs most commonly used to treat leishmaniasis, is equally susceptible to the tested PIs compared with a sensitive strain, thus suggesting that resistance to SbV does not result in cross-resistance to PIs. Importantly, the efficacy of PIs to reduce the intracellular growth of Leishmania parasites is also observed in MDMs coinfected with HIV-1.
Assuntos
Inibidores da Protease de HIV/farmacologia , Leishmania/efeitos dos fármacos , Leishmania/fisiologia , Leishmaniose Visceral/parasitologia , Animais , Linhagem Celular Tumoral , Humanos , Dose Letal Mediana , Macrófagos/parasitologia , Nelfinavir/farmacologia , Ritonavir/farmacologia , Saquinavir/farmacologiaRESUMO
Recent studies have shown that both Leishmania and HIV type-1 (HIV-1) hijack dendritic cell (DC) functions to escape immune surveillance using an array of elaborate strategies. Leishmania has developed a variety of adaptations to disrupt cellular defense mechanisms, whereas HIV-1 targets DCs to achieve a more efficient dissemination. The capacity of Leishmania and HIV-1 to target DCs through a common cell-surface molecule, namely DC-SIGN (dendritic cell specific ICAM-3-grabbing non-integrin), points to a possible dangerous liaison between these two pathogens. This review explores our knowledge of how Leishmania and HIV-1 interact dynamically with DCs, and how they exploit this cell type for their reciprocal benefit.
Assuntos
Células Dendríticas/parasitologia , Células Dendríticas/virologia , Infecções por HIV/imunologia , HIV-1/imunologia , Leishmania infantum/imunologia , Leishmaniose Visceral/imunologia , Animais , Moléculas de Adesão Celular/imunologia , Citocinas/imunologia , Células Dendríticas/imunologia , Infecções por HIV/parasitologia , Humanos , Leishmaniose Visceral/virologia , Receptores de Superfície Celular/imunologia , Linfócitos T/imunologia , Linfócitos T/parasitologia , Linfócitos T/virologiaRESUMO
Antimonial compounds are the mainstay for the treatment of infections with the protozoan parasite Leishmania. We present our studies on Leishmania infantum amastigote parasites selected for resistance to potassium antimonyl tartrate [Sb(III)]. Inside macrophages, the Sb(III)-selected cells are cross-resistant to sodium stibogluconate (Pentostam), the main drug used against Leishmania. Putative alterations in the level of expression of more than 40 genes were compared between susceptible and resistant axenic amastigotes using customized DNA microarrays. The expression of three genes coding for the ABC transporter MRPA (PGPA), S-adenosylhomocysteine hydrolase, and folylpolyglutamate synthase was found to be consistently increased. The levels of cysteine were found to be increased in the mutant. Transfection of the MRPA gene was shown to confer sodium stibogluconate resistance in intracellular parasites. This MRPA-mediated resistance could be reverted by using the glutathione biosynthesis-specific inhibitor buthionine sulfoximine. These results highlight for the first time the role of MRPA in antimony resistance in the amastigote stage of the parasite and suggest a strategy for reversing resistance.
Assuntos
Transportadores de Cassetes de Ligação de ATP/metabolismo , Antimônio/farmacologia , Glutationa/análogos & derivados , Leishmania infantum/efeitos dos fármacos , Glicoproteínas de Membrana/metabolismo , Proteínas de Protozoários/metabolismo , Espermidina/análogos & derivados , Animais , Gluconato de Antimônio e Sódio/farmacologia , Linhagem Celular , Cisteína/metabolismo , DNA de Protozoário/biossíntese , DNA de Protozoário/genética , Resistência a Medicamentos , Glutationa/metabolismo , Leishmania infantum/crescimento & desenvolvimento , Microscopia Confocal , Monócitos/efeitos dos fármacos , Análise de Sequência com Séries de Oligonucleotídeos , Ribonucleoproteínas/genética , Proteínas de Saccharomyces cerevisiae/genética , Espermidina/metabolismo , TransfecçãoRESUMO
Leishmania is a trypanosomatid parasite causing serious disease and displaying resistance to various drugs. Here, we present comparative proteomic analyses of Leishmania major parasites that have been either shocked with or selected in vitro for high level resistance to the model antifolate drug methotrexate. Numerous differentially expressed proteins were identified by these experiments. Some were associated with the stress response, whereas others were found to be overexpressed due to genetic linkage to primary resistance mediators present on DNA amplicons. Several proteins not previously associated with resistance were also identified. The role of one of these, methionine adenosyltransferase, was confirmed by gene transfection and metabolite analysis. After a single exposure to low levels of methotrexate, L. major methionine adenosyltransferase transfectants could grow at high concentrations of the drug. Methotrexate resistance was also correlated to increased cellular S-adenosylmethionine levels. The folate and S-adenosylmethionine regeneration pathways are intimately connected, which may provide a basis for this novel resistance phenotype. This thorough comparative proteomic analysis highlights the variety of responses required for drug resistance to be achieved.
Assuntos
Resistência a Medicamentos/genética , Leishmania major/metabolismo , Metionina Adenosiltransferase/fisiologia , Metotrexato , Proteínas de Protozoários/genética , S-Adenosilmetionina/fisiologia , Animais , Northern Blotting , Southern Blotting , Eletroforese em Gel Bidimensional , Expressão Gênica , Concentração de Íons de Hidrogênio , Hidroxiprostaglandina Desidrogenases/genética , Leishmania major/efeitos dos fármacos , Leishmania major/genética , Metionina Adenosiltransferase/genética , Metotrexato/farmacologia , Mutação , Fosfopiruvato Hidratase/genética , Reação em Cadeia da Polimerase , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por MatrizRESUMO
In the protozoan parasite Leishmania, drug resistance can be a complex phenomenon. Several metabolic pathways and membrane transporters are implicated in the resistance phenotype. To monitor the expression of these genes, we generated custom DNA microarrays with PCR fragments corresponding to 44 genes involved with drug resistance. Transcript profiling of arsenite and antimony resistant mutants with these arrays pinpointed a number of genes overexpressed in mutants, including the ABC transporter PGPA, the glutathione biosynthesis genes gamma-glutamylcysteine synthetase (GSH1) and the glutathione synthetase (GSH2). Competitive hybridisations with total RNA derived from sensitive and methotrexate resistant cells revealed the overexpression of genes coding for dihydrofolate reductase (DHFR-TS), pteridine reductase (PTR1) and S-adenosylmethionine synthase (MAT2) and a down regulation of one gene of the folate transporter (FT) family. By labelling the DNA of sensitive and resistant parasites we could also detect several gene amplification events using DNA microarrays including the amplification of the S-adenosyl homocysteine hydrolase gene (SAHH). Alteration in gene expression detected by microarrays was validated by northern blot analysis, while Southern blots indicated that most genes overexpressed were also amplified, although other mechanisms were also present. The microarrays were useful in the study of resistant parasites to pinpoint several genes linked to drug resistance.